PHILADELPHIA—The most vital component of avoiding drug shortages is early communication, officials from the U.S. Food & Drug Administration (FDA) said in a session at ACR Convergence 2022 in November. “Early notification is key in order to prevent and mitigate shortages,” said Hyun Son, PharmD, a member of the Drug Shortage Staff with the FDA…
Search results for: hospital
Advocacy Is Central to Patient Care, Distinguished Lecturer Says
When she saw vaping taking hold at a middle school, Kamala Nola, PharmD, MS, spoke up about concerns for the students’ risk of rheumatic disease and other health issues. At ACR Convergence 2022, Dr. Nola emphasized that every healthcare professional can act as an advocate through everyday actions.
Insights into Methotrexate Toxicity in Elderly Patients with Rheumatic Disease
Data from a small study show that severe methotrexate toxicity in patients who are 70 years of age and older and have rheumatic disease may be associated with poor renal function and the use of diuretic treatments.
Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw
A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.
Patients on Dialysis Taking Denosumab May Be at Risk of Severe Hypocalcemia
The FDA is investigating the risk of severe hypocalcemia with serious outcomes, such as hospitalization and death, in patients on dialysis taking denosumab.
Pseudo-What? Exploring the Classification Criteria Development Process for CPPD
PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation. An ACR Convergence 2022 session sought to update the audience on the progress to date in developing…
Blood Is Thicker Than Water: Updates on the ACR/EULAR Antiphospholipid Syndrome Classification Criteria
PHILADELPHIA—Ever since the seminal work of C. Lockard Conley, MD, in 1952 of the discovery of the lupus anticoagulant, antiphospholipid syndrome (APS) has been of great interest to rheumatologists, hematologists and many others. At ACR Convergence 2022, the session titled Draft ACR/EULAR Antiphospholipid Syndrome Classification Criteria sought to summarize the rigorous process that went into…
Fall 2022’s Awards, Appointments & Announcements in Rheumatology
Lupus Research Alliance Inaugurates Diversity Awards The Lupus Research Alliance (LRA) inaugurated two new award mechanisms this past summer with the goal of alleviating the racial disparities prevalent in both autoimmune diseases and the biomedical research community. Three notable early career scientists from under-represented groups received the Diversity in Lupus Research Career Development Awards, and…
The 2022 ACR Masters
Recognition as an ACR Master is one of the highest honors the College bestows. The designation of Master is conferred on ACR members, age 65 or older by Oct. 1 of the year in which they are nominated, who have made outstanding contributions to the ACR and the field of rheumatology through scholarly achievement and/or…
The 2022 ACR Awards of Distinction
During ACR Convergence 2022 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2022 Awards of Distinction, as well as the 2022 ACR Masters, recognized for their contributions to the field. See the November issue…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 328
- Next Page »